Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCEADE PanTumor PDAC substudy of precemtabart tocentecan in advanced pancreatic cancer
2024-517819-74-00Phase 2Authorised
- Sponsor
- Merck KGaA
- Start
- Jun 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of precemtabart tocentecan in pancreatic adenocarcinoma (PDAC), sponsored by Merck KGaA. Primary endpoint: Objective response. Planned start Jun 2025; status: authorised.
02
Drugs
precemtabart tocentecan
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-517819-74-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517819-74-00.